Dietary Supplement Listing Act of 2024
Latest Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S5552-5553)
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Dietary Supplement Listing Act of 2024 is a Senate bill introduced in the 118th Congress aimed at regulating dietary supplements. Although the official summary and full text are not available, the bill was referred to the Senate Committee on Health, Education, Labor, and Pensions for further consideration. The bill falls under the health policy area and appears to focus on establishing requirements or processes related to the listing of dietary supplements, which may involve oversight or reporting mechanisms.
This bill sought to introduce regulatory measures for dietary supplements but did not advance beyond committee referral and ultimately failed or expired without becoming law.
- The bill was introduced in the Senate during the 118th Congress and referred to the Committee on Health, Education, Labor, and Pensions.
- No official summary or full text is publicly available, limiting detailed analysis of specific provisions.
- The bill's status is recorded as failed or expired, indicating it did not pass into law during the legislative session.
['Manufacturers and distributors of dietary supplements, if the bill included clear listing requirements that could standardize market practices.', 'Consumers seeking greater transparency about dietary supplement contents and safety.', 'Regulatory agencies such as the Food and Drug Administration (FDA), if the bill enhanced their oversight capabilities.']
['Lack of publicly available full text and summary limits understanding of implementation requirements and enforcement mechanisms.', 'Potential costs associated with compliance for supplement manufacturers and administrative costs for regulatory agencies.', "Unclear authority and oversight provisions may affect how effectively the bill's goals could be achieved."]
The bill was introduced in the Senate and referred to a key committee responsible for health-related legislation. Its failure or expiration suggests it did not gain sufficient legislative support or priority during the 118th Congress. The absence of detailed public documentation restricts insight into the legislative debate or stakeholder positions.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could have led to increased regulatory oversight of dietary supplements, potentially affecting market dynamics and consumer confidence.', 'Enhanced listing requirements might have encouraged manufacturers to improve product transparency and safety standards.', 'Regulatory agencies might have required additional resources to implement and enforce new listing requirements.']
The absence of an official summary and full bill text presents a significant transparency challenge, limiting public and stakeholder ability to evaluate the bill's content and implications. This lack of information also complicates oversight and accountability efforts. The bill's failure to advance beyond committee referral further restricts insight into legislative deliberations and potential amendments.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.